Profiling of the mycobiome and metabolome: a comparative study of benign pulmonary nodules and lung adenocarcinoma
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1732958 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Weiyi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Metabolome, Lung Neoplasms, Mycobiome. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Lung adenocarcinoma (LUAD), the most common subtype of non-small cell lung cancer, is a form of malignant pulmonary nodule that requires clinical differentiation from benign pulmonary nodules (BPN). The mechanisms underlying the development of LUAD are complex, and effective non-invasive methods for differentiating BPN from LUAD are lacking. This study aimed not only to distinguish BPN from LUAD using gut fungi and serum metabolites, but also to establish an integrated network of gut fungi–metabolite–cytokine interactions.
Methods
Fecal and serum samples from individuals with BPN and patients with LUAD were subjected to internal transcribed spacer sequencing, ultra-performance liquid chromatography–tandem mass spectrometry, and multiplex Luminex assays to quantify gut fungi, metabolites, and cytokines, respectively.
Results
A significant difference in gut fungal communities was observed between the BPN and LUAD groups. Multiple genera and species were more abundant in LUAD than in BPN. Docosapentaenoic acid n-6 (DPAn-6), indole-3-propionic acid (IPA), and interferon-γ-induced protein 10 (IP-10) were significantly elevated in the LUAD group. The integrated model established using a combination of gut fungi and metabolites demonstrated excellent performance in distinguishing BPN from LUAD. A network of interactions was established among differentially abundant gut fungi, serum metabolites, and cytokines.
Conclusion
Our study identifies a novel panel of fungal and metabolite biomarkers for differentiating between BPN and LUAD, and constructs a multi-omics network that provides new insights into investigating the mechanistic role of gut mycobiota dysbiosis in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China.
- Department of Pharmacy, Medical Security Center Stationed in the 5th Medical Center Pharmacy Room, Chinese PLA General Hospital, Beijing, China.
- Department for Disinfection and Infection Control, Chinese PLA Center for Disease Control and Prevention, Beijing, China.
- Chinese PLA Medical School, Beijing, China.
- Southern Medical University, Guangzhou, China.
Zitieren
APA
Zhang, W., Dong, Y., Chen, F., Wang, F., Li, J., Liu, C., Liu, T., Han, L., & Jia, X. (2026). Profiling of the mycobiome and metabolome: a comparative study of benign pulmonary nodules and lung adenocarcinoma. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1732958
Vancouver
Zhang W, Dong Y, Chen F, Wang F, Li J, Liu C, et al. Profiling of the mycobiome and metabolome: a comparative study of benign pulmonary nodules and lung adenocarcinoma. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1732958
BibTeX
@article{Zhang2026,
author = {Zhang, Weiyi and Dong, Yuan and Chen, Fangyan and Wang, Fang and Li, Jiahui and Liu, Chunxi and Liu, Tianyi and Han, Li and Jia, Xiaodong},
title = {Profiling of the mycobiome and metabolome: a comparative study of benign pulmonary nodules and lung adenocarcinoma},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1732958}
}
EUVIMED